-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

When and Why Should Patients with Hematological Malignancies See a Palliative Care Specialist?

Program: Education Program
Session: Palliative Care in Hematological Malignancies
Sunday, December 6, 2015, 7:30 AM-9:00 AM
W308, Level 3 (Orange County Convention Center)
Monday, December 7, 2015, 7:00 AM-8:30 AM
W304EFGH, Level 3 (Orange County Convention Center)

Thomas W. LeBlanc, MD, MA

Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, NC

Disclosures: LeBlanc: Flatiron: Consultancy ; Epi-Q: Consultancy ; Helsinn Therapeutics: Honoraria , Research Funding ; Boehringer Ingelheim: Membership on an entity’s Board of Directors or advisory committees .

See more of: Palliative Care in Hematological Malignancies
See more of: Education Program
Previous Presentation | Next Presentation >>